Safety of Monoclonal Antibodies in Myeloma
Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.
Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.
While infusion reactions can occur, pre-medication is recommended. Also, reactions do not usually persist past the first infusion. For daratumumab, these reactions can also affect the upper respiratory system. Also in daratumumab, the agent can affect red cell cross-matching for transfusion. Therefore, all cross-matching should take place before infusions.
To learn more about these treatments, watch Monoclonal Antibodies in Multiple Myeloma.
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.
